Unlike Pfizer and Moderna’s messenger RNA vaccines, Novavax uses tiny particles studded with viral proteins, mixed with an immune-boosting compound called adjuvant. The vaccine is given as two doses three weeks apart.
Novavax’s COVID-19 vaccine candidate is 90.4 percent effective at preventing infection, according to a study published Dec. 15. The study also found the vaccine was 100 percent effective at preventing moderate and severe disease. The drugmaker has said its vaccine can protect against the omicron variant, though it’s unclear how strong the protection will be, according to The New York Times.
In 2020, the U.S. government ordered 110 million doses of the shot from Novavax.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
